NCT02068079View on ClinicalTrials.gov

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Melanoma

Interventions

DRUG

Vemurafenib and Trientine

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT02068079 - A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | Biotech Hunter | Biotech Hunter